

WH 04L Toolkit

Endometriosis Diagnosis and Management

Resource	Address
Agarwal SK, Chapron C, Giudice LC, et al. Clinical diagnosis of endometriosis: A call to action. <i>Am J Obstet Gynecol</i> . 2019;220(4):354.e1-354.e12. doi:10.1016/j.ajog.2018.12.039	https://pubmed.ncbi.nlm.nih.gov/30625295/
Bafort C, Beebejaun Y, Tomassetti C, Bosteels J, Duffy JM. Laparoscopic surgery for endometriosis. <i>Cochrane Database Syst Rev</i> . 2020;10(10):CD011031. doi:10.1002/14651858.CD011031.pub3	https://pubmed.ncbi.nlm.nih.gov/33095458/
Ballard K, Lowton K, Wright J. What's the delay? A qualitative study of women's experiences of reaching a diagnosis of endometriosis. <i>Fertil Steril</i> . 2006;86(5):1296-1301. doi:10.1016/j.fertnstert.2006.04.054	https://pubmed.ncbi.nlm.nih.gov/17070183/
Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: Endometriosis. <i>Hum Reprod Open</i> . 2022;2022(2):hoac009. doi:10.1093/hropen/hoac009	https://pubmed.ncbi.nlm.nih.gov/35350465/
Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. <i>Cochrane Database Syst Rev</i> . 2018;5(5):CD001019. doi:10.1002/14651858.CD001019.pub3	https://pubmed.ncbi.nlm.nih.gov/29786828/
Donnez J, Dolmans MM. Endometriosis and medical therapy: From progestogens to progesterone resistance to GnRH antagonists: A review. <i>J Clin Med</i> . 2021;10(5):1085. doi:10.3390/jcm10051085	https://pubmed.ncbi.nlm.nih.gov/33807739/
Falcone T, Flyckt R. Clinical management of endometriosis. <i>Obstet Gynecol</i> . 2018;131(3):557-571. doi:10.1097/AOG.0000000000002469	https://pubmed.ncbi.nlm.nih.gov/29420391/
Guo SW. Recurrence of endometriosis and its control. <i>Hum Reprod Update</i> . 2009;15(4):441-461. doi:10.1093/humupd/dmp007	https://pubmed.ncbi.nlm.nih.gov/19279046/
Kiesel L, Sourouni M. Diagnosis of endometriosis in the 21st century. <i>Climacteric</i> . 2019;22(3):296-302. doi:10.1080/13697137.2019.1578743	https://pubmed.ncbi.nlm.nih.gov/30905186/
Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: Clinical challenges and novel innovations. <i>Lancet</i> . 2021;397(10276):839-852. doi:10.1016/S0140-6736(21)00389-5	https://pubmed.ncbi.nlm.nih.gov/33640070/
Weisberg E, Fraser IS. Contraception and endometriosis: Challenges, efficacy, and therapeutic importance. <i>Open Access J Contracept</i> . 2015;6:105-115. doi:10.2147/OAJC.S56400	https://pubmed.ncbi.nlm.nih.gov/29386928/

Uterine Fibroids Diagnosis and Management

Resource	Address
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins–Gynecology. Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. <i>Obstet Gynecol.</i> 2021;137(6):e100-e115. doi:10.1097/AOG.0000000000004401	https://pubmed.ncbi.nlm.nih.gov/34011888/
Donnez J, Dolmans MM. Uterine fibroid management: From the present to the future. <i>Hum Reprod Update.</i> 2016;22(6):665-686. doi:10.1093/humupd/dmw023	https://pubmed.ncbi.nlm.nih.gov/27466209/
Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. <i>Int J Gynaecol Obstet.</i> 2020;149(1):3-9. doi:10.1002/ijgo.13102	https://pubmed.ncbi.nlm.nih.gov/31960950/
Kashani BN, Centini G, Morelli SS, Weiss G, Petraglia F. Role of medical management for uterine leiomyomas. <i>Best Pract Res Clin Obstet Gynaecol.</i> 2016;34:85-103. doi:10.1016/j.bpobgyn.2015.11.016	https://pubmed.ncbi.nlm.nih.gov/26796059/
Rovelli RJ, Cieri-Hutcherson NE, Hutcherson TC. Systematic review of oral pharmacotherapeutic options for the management of uterine fibroids. <i>J Am Pharm Assoc.</i> 2022;62(3):674-682.e5. doi:10.1016/j.japh.2022.02.004	https://pubmed.ncbi.nlm.nih.gov/35277362/

Clinical Trial Data

Resource	Address
Al-Hendy A, Lukes AS, Poindexter AN, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. <i>N Engl J Med.</i> 2021;384(7):630-642. doi:10.1056/NEJMoa2008283	https://pubmed.ncbi.nlm.nih.gov/33596357/
As-Sanie S, Becker CM, Johnson N, et al. Efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: Phase 3 randomized, double-blind, placebo-controlled study (SPIRIT 2). <i>Fertil Steril.</i> 2020;114(3):e77. doi:10.1016/j.fertnstert.2020.08.238	https://www.fertstert.org/article/S0015-0282(20)30992-4/fulltext
Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: A randomized clinical trial. <i>Fertil Steril.</i> 2020;114(1):44-55. doi:10.1016/j.fertnstert.2020.02.114	https://pubmed.ncbi.nlm.nih.gov/32505383/

Giudice LC, As-Sanie S, Arjona Ferreira JC, et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: Two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2). <i>Lancet</i> . 2022;399(10343):2267-2279. doi:10.1016/S0140-6736(22)00622-5	https://pubmed.ncbi.nlm.nih.gov/35717987/
Saraswat L, Bhattacharya S. Relugolix combination therapy for endometriosis pain. <i>Lancet</i> . 2022;399(10343):2244-2245. doi:10.1016/S0140-6736(22)00663-8	https://pubmed.ncbi.nlm.nih.gov/35717973/
Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. <i>N Engl J Med</i> . 2020;382(4):328-340. doi:10.1056/NEJMoa1904351	https://pubmed.ncbi.nlm.nih.gov/31971678/
Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. <i>N Engl J Med</i> . 2017;377(1):28-40. doi:10.1056/NEJMoa1700089	https://pubmed.ncbi.nlm.nih.gov/28525302/

Associations and Resources

Resource	Address
Endometriosis Foundation of America	https://www.endofound.org/
The Fibroid Foundation	https://www.fibroidfoundation.org/
Society for Women's Health Research	https://swhr.org/